GINA KOLATA

The effects of drugs that treat Alzheimer’s, cancer and other illnesses are often limited by the blood-brain barrier. A small study suggests a way forward.

The research, supported by the National Institutes of Health, may reassure some patients after a European drug safety agency raised concerns last year.

Pediatricians are hesitating to prescribe medicines like Wegovy, citing their newness and uncertainties around them.

People with the genetic disease have new opportunities to eliminate their symptoms, but the treatments come with obstacles that limit their reach.

The agency is looking into reports that some patients developed new blood cancers after receiving CAR-T treatments.

The first treatment that relies on CRISPR is expected to receive U.S. approval next month. But it may cost millions of dollars per patient.

Diverse data from the Million Veteran Program has already contributed to hundreds of medical studies, and the V.A. is continuing to recruit more participants.

The trial involved only 10 patients, but it suggests cholesterol can be permanently reduced with a single treatment for patients at risk of heart disease.

Zepbound, which is already sold by Eli Lilly as the diabetes treatment Mounjaro, was shown to reduce patients’ weight by as much as one-fifth in...

The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing...